


WHAT IS CLAIMED IS:

1. A method for treating a viral infection in a warm-blooded animal comprising administering to the warm-blooded animal a therapeutically effective amount of a compound of the following formula:



wherein,

R_1 is $-\text{COOR}_3$ or $-\text{CONHR}_3$;

when R_1 is $-\text{COOR}_3$,

R_3 is haloalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted benzyl, hydroxyalkyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl;

when R_1 is $-\text{CONHR}_3$,

R_3 is alkyl, haloalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted benzyl, hydroxyalkyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl; and

each of X and Y is independently hydrogen, alkyl, alkenyl, cycloalkyl, haloalkyl,

haloalkenyl, halogen, nitro, or amino;

a pharmaceutically acceptable salt thereof or a prodrug thereof.


2. A method according to claim 1 wherein said compound is in the form of a pharmaceutically acceptable salt thereof.

3. A method according to claim 2 wherein said pharmaceutically acceptable salt is a hydrochloride salt.

4. A method according to claim 1 wherein said compound is in the form of a prodrug thereof.

5. A method according to claim 1 wherein said compound is of the following formula

A-3:




5

A-3 .

6. A method according to claim 5 wherein Y is hydrogen or chloro, and R₃ is selected from the group consisting of alkyl, alkenyl, oligo(alkoxy)alkyl, and substituted or unsubstituted benzyl.

10 7. A method according to claim 1 wherein said compound is of the following formula

A-4:



A-4 .

15 8. A method according to claim 7 wherein Y is hydrogen or chloro, and R₃ is selected from the group consisting of alkyl, alkenyl, oligo(alkoxy)alkyl, and substituted or unsubstituted benzyl.

9. A method according to claim 1 wherein said compound is micronized and is suitable for administering to said warm-blooded animal by injection.

20

10. A method according to claim 1 wherein said compound is administered in an amount of from 10 mg/kg body weight to 10,000 mg/kg body weight.

11. A method according to claim 1 wherein said compound is administered orally, enterically,
25 intravenously, peritoneally, or by injection.

12. A method according to claim 1 wherein said compound is administered in a pharmaceutically acceptable carrier.
- 5 13. A method according to Claim 1 wherein said compound is coupled to a soluble polymer.
14. A method according to Claim 1 wherein said compound is coupled to a biodegradable polymer.
- 10 15. A method according to Claim 1 wherein the viral infection is due to an RNA virus.
16. The method according to Claim 15 wherein the RNA virus is a human immunodeficiency virus.